$90.360
-3.145 (-3.48%)Al cierre
Predicciones de precio
Ábrelo en la app para desbloquear previsiones a más largo plazo.
Predicción y previsión de SYRE por análisis de gráficos similares
Alphio's SYRE stock price prediction model matches the current Spyre Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $91.13 (+0.85%). The 1-week path is $94.14 (+4.18%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
¿Debería comprar acciones de Spyre Therapeutics Inc?
Spyre Therapeutics Inc is currently not a good buy. The stock is trading at $90.36, with a 5-day change of -15.15% and an RSI of 16.467, indicating it is oversold. Despite a strong year-to-date change of +195.49% and a one-year change of +443.36%, the recent insider selling and downgrades in analyst price targets suggest caution. The main risk is the significant net losses, with a reported net income of -$69 million for Q1 2026, which raises concerns about sustainability.
SYRE cerró en $90.36 el Friday, tras bajar -3.48%
Spyre Therapeutics Inc (SYRE) last closed at $90.36, losing -3.48%. These facts feed the 1-day and 1-week SYRE price prediction above.
Factores de la previsión
Los factores de la previsión de Spyre Therapeutics Inc (SYRE) combinan patrones gráficos similares, estacionalidad y medias móviles.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bullish
Patrones gráficos similares
Acciones cuya trayectoria reciente más se parece a la de SYRE, ordenadas por similitud.
Análisis de estacionalidad de SYRE
Historically the probability of a positive August return for SYRE is 66.67%. December offers the highest probability of a positive month at 100.00%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.